nodes	percent_of_prediction	percent_of_DWPC	metapath
Meropenem—Fluid overload—Carboplatin—esophageal cancer	0.0547	0.0547	CcSEcCtD
Meropenem—Phlebitis—Carboplatin—esophageal cancer	0.0287	0.0287	CcSEcCtD
Meropenem—Fluid overload—Cisplatin—esophageal cancer	0.0161	0.0161	CcSEcCtD
Meropenem—Haematocrit decreased—Methotrexate—esophageal cancer	0.0147	0.0147	CcSEcCtD
Meropenem—Platelet count decreased—Capecitabine—esophageal cancer	0.0124	0.0124	CcSEcCtD
Meropenem—Infection—Carboplatin—esophageal cancer	0.0121	0.0121	CcSEcCtD
Meropenem—Hypomagnesaemia—Capecitabine—esophageal cancer	0.0116	0.0116	CcSEcCtD
Meropenem—Oral candidiasis—Capecitabine—esophageal cancer	0.0116	0.0116	CcSEcCtD
Meropenem—Intestinal obstruction—Capecitabine—esophageal cancer	0.0108	0.0108	CcSEcCtD
Meropenem—Haemoglobin decreased—Capecitabine—esophageal cancer	0.0107	0.0107	CcSEcCtD
Meropenem—Ileus—Capecitabine—esophageal cancer	0.0104	0.0104	CcSEcCtD
Meropenem—Pain—Carboplatin—esophageal cancer	0.0104	0.0104	CcSEcCtD
Meropenem—Pleural effusion—Capecitabine—esophageal cancer	0.00961	0.00961	CcSEcCtD
Meropenem—Body temperature increased—Carboplatin—esophageal cancer	0.0096	0.0096	CcSEcCtD
Meropenem—Skin ulcer—Capecitabine—esophageal cancer	0.00945	0.00945	CcSEcCtD
Meropenem—Neuropathy—Cisplatin—esophageal cancer	0.00937	0.00937	CcSEcCtD
Meropenem—Injection site pain—Capecitabine—esophageal cancer	0.00902	0.00902	CcSEcCtD
Meropenem—Phlebitis—Cisplatin—esophageal cancer	0.00841	0.00841	CcSEcCtD
Meropenem—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00803	0.00803	CcSEcCtD
Meropenem—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00778	0.00778	CcSEcCtD
Meropenem—Inflammation—Capecitabine—esophageal cancer	0.00759	0.00759	CcSEcCtD
Meropenem—Pulmonary embolism—Capecitabine—esophageal cancer	0.00736	0.00736	CcSEcCtD
Meropenem—Injection site reaction—Capecitabine—esophageal cancer	0.00732	0.00732	CcSEcCtD
Meropenem—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00725	0.00725	CcSEcCtD
Meropenem—Melaena—Capecitabine—esophageal cancer	0.00719	0.00719	CcSEcCtD
Meropenem—Pleural effusion—Methotrexate—esophageal cancer	0.00715	0.00715	CcSEcCtD
Meropenem—Urinary incontinence—Capecitabine—esophageal cancer	0.00711	0.00711	CcSEcCtD
Meropenem—Colitis—Capecitabine—esophageal cancer	0.00707	0.00707	CcSEcCtD
Meropenem—Skin ulcer—Methotrexate—esophageal cancer	0.00704	0.00704	CcSEcCtD
Meropenem—Candida infection—Capecitabine—esophageal cancer	0.00703	0.00703	CcSEcCtD
Meropenem—Neuropathy—Capecitabine—esophageal cancer	0.00691	0.00691	CcSEcCtD
Meropenem—Blood creatinine increased—Cisplatin—esophageal cancer	0.00679	0.00679	CcSEcCtD
Meropenem—Hypokalaemia—Cisplatin—esophageal cancer	0.0066	0.0066	CcSEcCtD
Meropenem—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00653	0.00653	CcSEcCtD
Meropenem—Apnoea—Methotrexate—esophageal cancer	0.00646	0.00646	CcSEcCtD
Meropenem—Sepsis—Capecitabine—esophageal cancer	0.00639	0.00639	CcSEcCtD
Meropenem—Phlebitis—Capecitabine—esophageal cancer	0.0062	0.0062	CcSEcCtD
Meropenem—Thrombophlebitis—Capecitabine—esophageal cancer	0.00617	0.00617	CcSEcCtD
Meropenem—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00614	0.00614	CcSEcCtD
Meropenem—Glossitis—Methotrexate—esophageal cancer	0.00595	0.00595	CcSEcCtD
Meropenem—Hepatic failure—Capecitabine—esophageal cancer	0.00595	0.00595	CcSEcCtD
Meropenem—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00592	0.00592	CcSEcCtD
Meropenem—Inflammation—Methotrexate—esophageal cancer	0.00565	0.00565	CcSEcCtD
Meropenem—Respiratory failure—Methotrexate—esophageal cancer	0.00558	0.00558	CcSEcCtD
Meropenem—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00551	0.00551	CcSEcCtD
Meropenem—Renal failure—Cisplatin—esophageal cancer	0.00549	0.00549	CcSEcCtD
Meropenem—Vaginal inflammation—Methotrexate—esophageal cancer	0.00548	0.00548	CcSEcCtD
Meropenem—Pulmonary embolism—Methotrexate—esophageal cancer	0.00548	0.00548	CcSEcCtD
Meropenem—Myocardial infarction—Cisplatin—esophageal cancer	0.00548	0.00548	CcSEcCtD
Meropenem—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00548	0.00548	CcSEcCtD
Meropenem—Cardiac failure—Capecitabine—esophageal cancer	0.00547	0.00547	CcSEcCtD
Meropenem—Melaena—Methotrexate—esophageal cancer	0.00535	0.00535	CcSEcCtD
Meropenem—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00534	0.00534	CcSEcCtD
Meropenem—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00528	0.00528	CcSEcCtD
Meropenem—Vaginal infection—Methotrexate—esophageal cancer	0.00517	0.00517	CcSEcCtD
Meropenem—Bradycardia—Cisplatin—esophageal cancer	0.0051	0.0051	CcSEcCtD
Meropenem—Cardiac arrest—Capecitabine—esophageal cancer	0.00508	0.00508	CcSEcCtD
Meropenem—Blood creatinine increased—Capecitabine—esophageal cancer	0.00501	0.00501	CcSEcCtD
Meropenem—Pulmonary oedema—Methotrexate—esophageal cancer	0.00488	0.00488	CcSEcCtD
Meropenem—Hypokalaemia—Capecitabine—esophageal cancer	0.00486	0.00486	CcSEcCtD
Meropenem—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00481	0.00481	CcSEcCtD
Meropenem—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00481	0.00481	CcSEcCtD
Meropenem—Sepsis—Methotrexate—esophageal cancer	0.00475	0.00475	CcSEcCtD
Meropenem—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00471	0.00471	CcSEcCtD
Meropenem—Abdominal distension—Capecitabine—esophageal cancer	0.00465	0.00465	CcSEcCtD
Meropenem—Asthma—Capecitabine—esophageal cancer	0.00462	0.00462	CcSEcCtD
Meropenem—Thrombophlebitis—Methotrexate—esophageal cancer	0.00459	0.00459	CcSEcCtD
Meropenem—Immune system disorder—Cisplatin—esophageal cancer	0.00453	0.00453	CcSEcCtD
Meropenem—Hepatic failure—Methotrexate—esophageal cancer	0.00443	0.00443	CcSEcCtD
Meropenem—Erythema—Cisplatin—esophageal cancer	0.00436	0.00436	CcSEcCtD
Meropenem—Neutropenia—Capecitabine—esophageal cancer	0.00432	0.00432	CcSEcCtD
Meropenem—Dysuria—Capecitabine—esophageal cancer	0.00432	0.00432	CcSEcCtD
Meropenem—Flatulence—Cisplatin—esophageal cancer	0.0043	0.0043	CcSEcCtD
Meropenem—Pneumonia—Capecitabine—esophageal cancer	0.00414	0.00414	CcSEcCtD
Meropenem—Infestation NOS—Capecitabine—esophageal cancer	0.00412	0.00412	CcSEcCtD
Meropenem—Infestation—Capecitabine—esophageal cancer	0.00412	0.00412	CcSEcCtD
Meropenem—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00408	0.00408	CcSEcCtD
Meropenem—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00406	0.00406	CcSEcCtD
Meropenem—Renal failure—Capecitabine—esophageal cancer	0.00405	0.00405	CcSEcCtD
Meropenem—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00404	0.00404	CcSEcCtD
Meropenem—Myocardial infarction—Capecitabine—esophageal cancer	0.00404	0.00404	CcSEcCtD
Meropenem—Anaemia—Cisplatin—esophageal cancer	0.00403	0.00403	CcSEcCtD
Meropenem—Jaundice—Capecitabine—esophageal cancer	0.00401	0.00401	CcSEcCtD
Meropenem—Malaise—Cisplatin—esophageal cancer	0.00394	0.00394	CcSEcCtD
Meropenem—Leukopenia—Cisplatin—esophageal cancer	0.00391	0.00391	CcSEcCtD
Meropenem—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00389	0.00389	CcSEcCtD
Meropenem—Epistaxis—Capecitabine—esophageal cancer	0.00388	0.00388	CcSEcCtD
Meropenem—Agranulocytosis—Capecitabine—esophageal cancer	0.00384	0.00384	CcSEcCtD
Meropenem—Bradycardia—Capecitabine—esophageal cancer	0.00376	0.00376	CcSEcCtD
Meropenem—Haemoglobin—Capecitabine—esophageal cancer	0.00371	0.00371	CcSEcCtD
Meropenem—Anxiety—Cisplatin—esophageal cancer	0.0037	0.0037	CcSEcCtD
Meropenem—Haemorrhage—Capecitabine—esophageal cancer	0.0037	0.0037	CcSEcCtD
Meropenem—Hepatitis—Capecitabine—esophageal cancer	0.0037	0.0037	CcSEcCtD
Meropenem—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00369	0.00369	CcSEcCtD
Meropenem—Pharyngitis—Capecitabine—esophageal cancer	0.00367	0.00367	CcSEcCtD
Meropenem—Oedema peripheral—Capecitabine—esophageal cancer	0.00364	0.00364	CcSEcCtD
Meropenem—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00358	0.00358	CcSEcCtD
Meropenem—Oedema—Cisplatin—esophageal cancer	0.00356	0.00356	CcSEcCtD
Meropenem—Anaphylactic shock—Cisplatin—esophageal cancer	0.00356	0.00356	CcSEcCtD
Meropenem—Infection—Cisplatin—esophageal cancer	0.00354	0.00354	CcSEcCtD
Meropenem—Erythema multiforme—Capecitabine—esophageal cancer	0.00349	0.00349	CcSEcCtD
Meropenem—Nervous system disorder—Cisplatin—esophageal cancer	0.00349	0.00349	CcSEcCtD
Meropenem—Thrombocytopenia—Cisplatin—esophageal cancer	0.00349	0.00349	CcSEcCtD
Meropenem—Tachycardia—Cisplatin—esophageal cancer	0.00348	0.00348	CcSEcCtD
Meropenem—Skin disorder—Cisplatin—esophageal cancer	0.00346	0.00346	CcSEcCtD
Meropenem—Hyperhidrosis—Cisplatin—esophageal cancer	0.00344	0.00344	CcSEcCtD
Meropenem—Asthma—Methotrexate—esophageal cancer	0.00344	0.00344	CcSEcCtD
Meropenem—Eosinophilia—Methotrexate—esophageal cancer	0.0034	0.0034	CcSEcCtD
Meropenem—Anorexia—Cisplatin—esophageal cancer	0.0034	0.0034	CcSEcCtD
Meropenem—Immune system disorder—Capecitabine—esophageal cancer	0.00334	0.00334	CcSEcCtD
Meropenem—Hypotension—Cisplatin—esophageal cancer	0.00333	0.00333	CcSEcCtD
Meropenem—Chills—Capecitabine—esophageal cancer	0.00332	0.00332	CcSEcCtD
Meropenem—Erythema—Capecitabine—esophageal cancer	0.00322	0.00322	CcSEcCtD
Meropenem—Dysuria—Methotrexate—esophageal cancer	0.00321	0.00321	CcSEcCtD
Meropenem—Neutropenia—Methotrexate—esophageal cancer	0.00321	0.00321	CcSEcCtD
Meropenem—Paraesthesia—Cisplatin—esophageal cancer	0.0032	0.0032	CcSEcCtD
Meropenem—Dyspnoea—Cisplatin—esophageal cancer	0.00318	0.00318	CcSEcCtD
Meropenem—Flatulence—Capecitabine—esophageal cancer	0.00317	0.00317	CcSEcCtD
Meropenem—Dysgeusia—Capecitabine—esophageal cancer	0.00315	0.00315	CcSEcCtD
Meropenem—Back pain—Capecitabine—esophageal cancer	0.00311	0.00311	CcSEcCtD
Meropenem—Decreased appetite—Cisplatin—esophageal cancer	0.0031	0.0031	CcSEcCtD
Meropenem—Pneumonia—Methotrexate—esophageal cancer	0.00308	0.00308	CcSEcCtD
Meropenem—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00308	0.00308	CcSEcCtD
Meropenem—Infestation NOS—Methotrexate—esophageal cancer	0.00307	0.00307	CcSEcCtD
Meropenem—Infestation—Methotrexate—esophageal cancer	0.00307	0.00307	CcSEcCtD
Meropenem—Pain—Cisplatin—esophageal cancer	0.00305	0.00305	CcSEcCtD
Meropenem—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00304	0.00304	CcSEcCtD
Meropenem—Renal failure—Methotrexate—esophageal cancer	0.00301	0.00301	CcSEcCtD
Meropenem—Anaemia—Capecitabine—esophageal cancer	0.00297	0.00297	CcSEcCtD
Meropenem—Sweating—Methotrexate—esophageal cancer	0.00294	0.00294	CcSEcCtD
Meropenem—Feeling abnormal—Cisplatin—esophageal cancer	0.00294	0.00294	CcSEcCtD
Meropenem—Malaise—Capecitabine—esophageal cancer	0.0029	0.0029	CcSEcCtD
Meropenem—Hepatobiliary disease—Methotrexate—esophageal cancer	0.0029	0.0029	CcSEcCtD
Meropenem—Epistaxis—Methotrexate—esophageal cancer	0.00289	0.00289	CcSEcCtD
Meropenem—Syncope—Capecitabine—esophageal cancer	0.00289	0.00289	CcSEcCtD
Meropenem—Leukopenia—Capecitabine—esophageal cancer	0.00288	0.00288	CcSEcCtD
Meropenem—Agranulocytosis—Methotrexate—esophageal cancer	0.00286	0.00286	CcSEcCtD
Meropenem—Loss of consciousness—Capecitabine—esophageal cancer	0.00283	0.00283	CcSEcCtD
Meropenem—Body temperature increased—Cisplatin—esophageal cancer	0.00282	0.00282	CcSEcCtD
Meropenem—Cough—Capecitabine—esophageal cancer	0.00281	0.00281	CcSEcCtD
Meropenem—Hypertension—Capecitabine—esophageal cancer	0.00278	0.00278	CcSEcCtD
Meropenem—Haemoglobin—Methotrexate—esophageal cancer	0.00277	0.00277	CcSEcCtD
Meropenem—Hepatitis—Methotrexate—esophageal cancer	0.00275	0.00275	CcSEcCtD
Meropenem—Haemorrhage—Methotrexate—esophageal cancer	0.00275	0.00275	CcSEcCtD
Meropenem—Chest pain—Capecitabine—esophageal cancer	0.00274	0.00274	CcSEcCtD
Meropenem—Pharyngitis—Methotrexate—esophageal cancer	0.00273	0.00273	CcSEcCtD
Meropenem—Anxiety—Capecitabine—esophageal cancer	0.00273	0.00273	CcSEcCtD
Meropenem—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00272	0.00272	CcSEcCtD
Meropenem—Confusional state—Capecitabine—esophageal cancer	0.00265	0.00265	CcSEcCtD
Meropenem—Oedema—Capecitabine—esophageal cancer	0.00263	0.00263	CcSEcCtD
Meropenem—Hypersensitivity—Cisplatin—esophageal cancer	0.00262	0.00262	CcSEcCtD
Meropenem—Infection—Capecitabine—esophageal cancer	0.00261	0.00261	CcSEcCtD
Meropenem—Erythema multiforme—Methotrexate—esophageal cancer	0.0026	0.0026	CcSEcCtD
Meropenem—Shock—Capecitabine—esophageal cancer	0.00258	0.00258	CcSEcCtD
Meropenem—Nervous system disorder—Capecitabine—esophageal cancer	0.00258	0.00258	CcSEcCtD
Meropenem—Thrombocytopenia—Capecitabine—esophageal cancer	0.00257	0.00257	CcSEcCtD
Meropenem—Tachycardia—Capecitabine—esophageal cancer	0.00256	0.00256	CcSEcCtD
Meropenem—Asthenia—Cisplatin—esophageal cancer	0.00256	0.00256	CcSEcCtD
Meropenem—Skin disorder—Capecitabine—esophageal cancer	0.00255	0.00255	CcSEcCtD
Meropenem—Hyperhidrosis—Capecitabine—esophageal cancer	0.00254	0.00254	CcSEcCtD
Meropenem—Anorexia—Capecitabine—esophageal cancer	0.0025	0.0025	CcSEcCtD
Meropenem—Immune system disorder—Methotrexate—esophageal cancer	0.00249	0.00249	CcSEcCtD
Meropenem—Chills—Methotrexate—esophageal cancer	0.00247	0.00247	CcSEcCtD
Meropenem—Hypotension—Capecitabine—esophageal cancer	0.00245	0.00245	CcSEcCtD
Meropenem—Diarrhoea—Cisplatin—esophageal cancer	0.00244	0.00244	CcSEcCtD
Meropenem—Erythema—Methotrexate—esophageal cancer	0.0024	0.0024	CcSEcCtD
Meropenem—Insomnia—Capecitabine—esophageal cancer	0.00238	0.00238	CcSEcCtD
Meropenem—Paraesthesia—Capecitabine—esophageal cancer	0.00236	0.00236	CcSEcCtD
Meropenem—Dysgeusia—Methotrexate—esophageal cancer	0.00235	0.00235	CcSEcCtD
Meropenem—Dyspnoea—Capecitabine—esophageal cancer	0.00234	0.00234	CcSEcCtD
Meropenem—Back pain—Methotrexate—esophageal cancer	0.00232	0.00232	CcSEcCtD
Meropenem—Dyspepsia—Capecitabine—esophageal cancer	0.00231	0.00231	CcSEcCtD
Meropenem—Decreased appetite—Capecitabine—esophageal cancer	0.00228	0.00228	CcSEcCtD
Meropenem—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00227	0.00227	CcSEcCtD
Meropenem—Vomiting—Cisplatin—esophageal cancer	0.00226	0.00226	CcSEcCtD
Meropenem—Rash—Cisplatin—esophageal cancer	0.00225	0.00225	CcSEcCtD
Meropenem—Constipation—Capecitabine—esophageal cancer	0.00225	0.00225	CcSEcCtD
Meropenem—Pain—Capecitabine—esophageal cancer	0.00225	0.00225	CcSEcCtD
Meropenem—Dermatitis—Cisplatin—esophageal cancer	0.00224	0.00224	CcSEcCtD
Meropenem—Anaemia—Methotrexate—esophageal cancer	0.00221	0.00221	CcSEcCtD
Meropenem—Feeling abnormal—Capecitabine—esophageal cancer	0.00216	0.00216	CcSEcCtD
Meropenem—Malaise—Methotrexate—esophageal cancer	0.00216	0.00216	CcSEcCtD
Meropenem—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00215	0.00215	CcSEcCtD
Meropenem—Leukopenia—Methotrexate—esophageal cancer	0.00214	0.00214	CcSEcCtD
Meropenem—Nausea—Cisplatin—esophageal cancer	0.00212	0.00212	CcSEcCtD
Meropenem—Cough—Methotrexate—esophageal cancer	0.00209	0.00209	CcSEcCtD
Meropenem—Urticaria—Capecitabine—esophageal cancer	0.00209	0.00209	CcSEcCtD
Meropenem—Body temperature increased—Capecitabine—esophageal cancer	0.00208	0.00208	CcSEcCtD
Meropenem—Abdominal pain—Capecitabine—esophageal cancer	0.00208	0.00208	CcSEcCtD
Meropenem—Chest pain—Methotrexate—esophageal cancer	0.00204	0.00204	CcSEcCtD
Meropenem—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00203	0.00203	CcSEcCtD
Meropenem—Confusional state—Methotrexate—esophageal cancer	0.00197	0.00197	CcSEcCtD
Meropenem—Anaphylactic shock—Methotrexate—esophageal cancer	0.00195	0.00195	CcSEcCtD
Meropenem—Infection—Methotrexate—esophageal cancer	0.00194	0.00194	CcSEcCtD
Meropenem—Hypersensitivity—Capecitabine—esophageal cancer	0.00193	0.00193	CcSEcCtD
Meropenem—Nervous system disorder—Methotrexate—esophageal cancer	0.00192	0.00192	CcSEcCtD
Meropenem—Thrombocytopenia—Methotrexate—esophageal cancer	0.00191	0.00191	CcSEcCtD
Meropenem—Skin disorder—Methotrexate—esophageal cancer	0.0019	0.0019	CcSEcCtD
Meropenem—Hyperhidrosis—Methotrexate—esophageal cancer	0.00189	0.00189	CcSEcCtD
Meropenem—Asthenia—Capecitabine—esophageal cancer	0.00188	0.00188	CcSEcCtD
Meropenem—Anorexia—Methotrexate—esophageal cancer	0.00186	0.00186	CcSEcCtD
Meropenem—Pruritus—Capecitabine—esophageal cancer	0.00186	0.00186	CcSEcCtD
Meropenem—Hypotension—Methotrexate—esophageal cancer	0.00183	0.00183	CcSEcCtD
Meropenem—Diarrhoea—Capecitabine—esophageal cancer	0.0018	0.0018	CcSEcCtD
Meropenem—Insomnia—Methotrexate—esophageal cancer	0.00177	0.00177	CcSEcCtD
Meropenem—Paraesthesia—Methotrexate—esophageal cancer	0.00176	0.00176	CcSEcCtD
Meropenem—Dyspnoea—Methotrexate—esophageal cancer	0.00174	0.00174	CcSEcCtD
Meropenem—Somnolence—Methotrexate—esophageal cancer	0.00174	0.00174	CcSEcCtD
Meropenem—Dizziness—Capecitabine—esophageal cancer	0.00174	0.00174	CcSEcCtD
Meropenem—Dyspepsia—Methotrexate—esophageal cancer	0.00172	0.00172	CcSEcCtD
Meropenem—Decreased appetite—Methotrexate—esophageal cancer	0.0017	0.0017	CcSEcCtD
Meropenem—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00169	0.00169	CcSEcCtD
Meropenem—Pain—Methotrexate—esophageal cancer	0.00167	0.00167	CcSEcCtD
Meropenem—Vomiting—Capecitabine—esophageal cancer	0.00167	0.00167	CcSEcCtD
Meropenem—Rash—Capecitabine—esophageal cancer	0.00166	0.00166	CcSEcCtD
Meropenem—Dermatitis—Capecitabine—esophageal cancer	0.00165	0.00165	CcSEcCtD
Meropenem—Headache—Capecitabine—esophageal cancer	0.00165	0.00165	CcSEcCtD
Meropenem—Feeling abnormal—Methotrexate—esophageal cancer	0.00161	0.00161	CcSEcCtD
Meropenem—Gastrointestinal pain—Methotrexate—esophageal cancer	0.0016	0.0016	CcSEcCtD
Meropenem—Nausea—Capecitabine—esophageal cancer	0.00156	0.00156	CcSEcCtD
Meropenem—Urticaria—Methotrexate—esophageal cancer	0.00155	0.00155	CcSEcCtD
Meropenem—Body temperature increased—Methotrexate—esophageal cancer	0.00155	0.00155	CcSEcCtD
Meropenem—Abdominal pain—Methotrexate—esophageal cancer	0.00155	0.00155	CcSEcCtD
Meropenem—Hypersensitivity—Methotrexate—esophageal cancer	0.00144	0.00144	CcSEcCtD
Meropenem—Asthenia—Methotrexate—esophageal cancer	0.0014	0.0014	CcSEcCtD
Meropenem—Pruritus—Methotrexate—esophageal cancer	0.00138	0.00138	CcSEcCtD
Meropenem—Diarrhoea—Methotrexate—esophageal cancer	0.00134	0.00134	CcSEcCtD
Meropenem—Dizziness—Methotrexate—esophageal cancer	0.00129	0.00129	CcSEcCtD
Meropenem—Vomiting—Methotrexate—esophageal cancer	0.00124	0.00124	CcSEcCtD
Meropenem—Rash—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Meropenem—Dermatitis—Methotrexate—esophageal cancer	0.00123	0.00123	CcSEcCtD
Meropenem—Headache—Methotrexate—esophageal cancer	0.00122	0.00122	CcSEcCtD
Meropenem—Nausea—Methotrexate—esophageal cancer	0.00116	0.00116	CcSEcCtD
